China-based Sinovac Biotech, which earlier this week became the target of a take-private bid from its chairman and SAIF Partners, has received a competing offer from a consortium that includes China International Capital Corporation (CICC).
BeiGene, a Chinese cancer drug developer backed by Hillhouse Capital and CITIC Private Equity, closed up 18% on its first day of trading on NASDAQ following a $158.4 million IPO.
SAIF Partners has teamed up with the chairman and CEO of Chinese biopharmaceutical player Sinovac Biotech to submit a $345 million buyout offer for the NASDAQ-listed company.
ADV Partners has invested $45 million in Indian hospital chain Dr. Agarwal's Healthcare, providing an exit for existing backer Evolvence Capital.
We Doctor Group, a Chinese online healthcare information portal formerly known as Guahao.com, has raised a further $20 million from Shanghai-listed property developer Shandong Tyan Home.
Adagene, a China-based life sciences company focused on smart antibody technology, has raised a $28 million Series B round led by GP Healthcare Capital, the medical-focused subsidiary of China's GP Capital.
KTB Ventures and Jolly Innovation Ventures have led a $30 million Series B round for Shanghai-based cancer therapy developer CARsgen Therapeutics.
Qiming Venture Partners has announced that it has closed its fifth US dollar-denominated China VC fund at $648 million.
The Abraaj Group buys India's CARE Hospitals from Advent International with a view to taking the business into new markets
London-based Cocoon Networks, which is backed private equity firms China Equity Group and Hanxin Capital, has launched a GBP500 million ($720 million) venture fund to invest in UK and European technology start-ups.
J-Star has made another investment intended to leverage Japan’s aging population with the acquisition of Platia, a nursing services business that specializes in caring for people with dementia.
The Abraaj Group has agreed to buy CARE Hospitals, India's fifth-largest healthcare provider from Advent International.
Advantech Capital, one of two new funds launched by executives from Chinese GP New Horizon Capital, has led a $100 million Series B round of funding for biotech start-up Zai Lab.
Ekuinas, a private equity firm backed by the government of Malaysia, has invested a total of MYR79.8 million ($18.1 million) in two companies that support the healthcare sector.
Singapore-based biotech developer Aslan Pharmaceuticals has closed its Series C round of funding at $43 million with additional capital from new investor MVP Capital Partners.
A PE-backed consortium that includes Meinian Onehealth has increased its take-private offer for iKang Healthcare Group in response to a rival consortium led by the company’s founder bringing in a string of heavyweight investors.
Alibaba Group and Ontario Teachers’ Pension Plan (OTPP) have joined a consortium led by the founder and CEO of iKang Healthcare Group that is involved in a competitive battle to privatize the US-listed company.
Thyrocare Technologies, an Indian diagnostics company with several private equity backers, has filed for a domestic IPO.
Shares in Indian medical diagnostics service Dr. Lal PathLabs gained more than 50% on debut following the company's INR6.3 billion ($95 million) IPO.
WuXi Healthcare Ventures, a corporate venture arm owned by China-based WuXi PharmaTech, has closed its second early-stage healthcare fund at $290 million, exceeding the target of $200 million.
A PE-backed consortium that includes Meinian Onehealth has submitted a revised and improved proposal to acquire US-listed iKang Healthcare Group.
The Goldstone Investment-managed CITIC M&A Fund and Legend Capital have led a $280 million round of financing for Pharmaron, a Chinese contract research organization (CRO) company.
A consortium comprising the founder and CEO of WuXi PharmaTech and several PE investors has completed the privatization of the China-based provider of contract R&D services to global pharmaceutical companies.
The Overseas Private Investment Corporation (OPIC) has committed $200 million to LeapFrog Investments as part of a $1 billion financing drive for development-oriented funds in emerging markets.